HSIC Henry Schein
WatchlistHenry Schein News
Henry Schein to Present at Nasdaq's 49th Investor Conference
Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that the Company will present at Nasdaq's 49th Investor
Stifel Reiterates Buy on Henry Schein, Maintains $75 Price Target
Stifel analyst Jonathan Block reiterates Henry Schein with a Buy and maintains $75 price target.
Jefferies U.S. Quant Portfolio - ROIC Stars and High Yield
Analysts Offer Insights on Healthcare Companies: Agilent (A), Henry Schein (HSIC) and Biogen (BIIB)
Henry Schein (HSIC) Q3 Earnings Analysis: A Medical Stock to Watch?
Express News | Henry Schein Gets Deficiency Notice From Nasdaq Regarding Requirement To Timely File Quarterly Report
Henry Schein Announces Receipt of Deficiency Notice From Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-Q
Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announces that it received an expected notice (the "Notice") on November 13, 2023
These Analysts Slash Their Forecasts On Henry Schein After Q3 Results
Henry Schein Inc (NASDAQ:HSIC) posted downbeat sales results for its third quarter on Monday. Henry Schein reported quarterly sales of $3.16 billion, slightly missing the consensus of $3.21 billion.
What 5 Analyst Ratings Have To Say About Henry Schein
Analysts have provided the following ratings for Henry Schein (NASDAQ:HSIC) within the last quarter: BullishSomewhat BullishIndifferentSomewhat BearishBearishTotal Ratings12110Last 30D010101M Ago11100
Barrington Cuts Price Target on Henry Schein to $82 From $90, Maintains Outperform Rating
Henry Schein (HSIC) has an average rating of hold and price targets ranging from $65 to $90, according to analysts polled by Capital IQ. Price: 68.51, Change: +1.01, Percent Change: +1.5
Morgan Stanley Maintains Underweight on Henry Schein, Lowers Price Target to $65
Morgan Stanley analyst Erin Wright maintains Henry Schein with a Underweight and lowers the price target from $69 to $65.
Henry Schein Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 11/14/2023 -5.11% Morgan Stanley $69 → $65 Maintains Underweight 11/10/2023 2.19% Stifel → $70 Upgrades Ho
Piper Sandler Keeps Their Buy Rating on Henry Schein (HSIC)
Fear Continues To Grip Markets Ahead Of Inflation Data
The CNN Money Fear and Greed index showed some easing in the overall fear level, with the index remaining in the "Fear" zone on Monday. U.S. stocks closed mixed on Monday, ahead of the release of key
Henry Schein (HSIC) Q3 Revenues Miss, 2023 Guidance Cut
U.S. Shares Mixed at Close of Trade; Dow Jones Industrial Average up 0.16%
Sector Update: Health Care Stocks Higher in Afternoon Trading
Health care stocks rose Monday afternoon with the NYSE Health Care Index adding 0.6% and the Health Care Select Sector SPDR Fund (XLV) up 0.5%. The iShares Biotechnology ETF (IBB) fell 0.6%. In corpor
Sector Update: Health Care
Health care stocks rose Monday afternoon with the NYSE Health Care Index adding 0.6% and the Health Care Select Sector SPDR Fund (XLV) up 0.5%. The iShares Biotechnology ETF (IBB) fell 0.6%. In corpor
Express News | Henry Schein Shares Are Trading Higher After the Company Reported Q3 Results and Issued FY23 Guidance
Research Alert: CFRA Maintains Hold Opinion On Shares Of Henry Schein Inc.
CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We lower our 12-month target price by $8